



Adult CIRB - Late Phase Emphasis Meeting Agenda

May 7, 2026

I New Study - Initial Review

EA4241, A Two Cohort Randomized Study for Patients with High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse (Version Date 04/14/26)

II New Study - Initial Review

S2511, Randomized Phase III Trial of Multimodality Therapy versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) de novo (AJCC Stage IV) Oligometastatic Breast Cancer with Response to Initial Chemotherapy (Version Date 03/18/26)

III New Study - Initial Review

S2505, Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) versus Standard Fractionation (RT-25) for Stage II-IIIB Extremity, Resectable Soft Tissue Sarcoma (Version Date 03/09/26)

IV Amendment

S1925, Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (Version Date 03/27/26)

V Amendment

MM10A-EA02, A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy (Version Date 03/20/26)

VI Continuing Review

EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy (Version Date 12/09/22)

VII Continuing Review

EA9171, BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD (Version Date 01/12/26)

VIII Continuing Review

NRG-BN003, Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma (Version Date 03/16/26)

IX Continuing Review

NRG-BN014, A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM) (Version Date 07/02/25)

X Continuing Review

NRG-GI004, Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (Version Date 06/05/25)

XI Continuing Review

NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) (Version Date 03/27/25)

XII Continuing Review

S2312, A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature (CARAVAN) (Version Date 11/20/25)

XIII Continuing Review

MM1YA-S01, A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial (Version Date 11/14/25)
